Skip to main content

Advertisement

SpringerLink
Log in

Serum Pentosidine Level in Healthy Ageing and Its Association with Age-Related Disease

  • Medicine
  • Published:
SN Comprehensive Clinical Medicine Aims and scope Submit manuscript

Abstract

Advanced glycation end products (AGEs) arise from non-enzymatic reactions between extracellular proteins and glucose. AGEs’ formation occurs during normal ageing but distinctly accelerate with the progression of chronic disease. Pentosidine is a very sensitive marker for all AGEs. We investigated whether serum pentosidine was increased and correlated with healthy elderly individuals (80–102 years) and the disease groups (hypertension 60–77 years; and coronary artery disease 60–77 years). Measurement of serum pentosidine levels in healthy elderly individuals is n = 38, hypertensive patients n = 38, and coronary artery diseases n = 31(treated with drugs). Drugs for the treatment of CAD work as inhibitors of advanced glycation end products. Serum levels of pentosidine are measured by using sandwich ELISA. Serum pentosidine concentrations were significantly higher in hypertensive patients (1910.5 ± 302.6 pmol/ml) in comparison with healthy elderly individuals (1605.1 ± 596.5 pmol/ml) as well as in coronary artery disease (1495 ± 531.8 pmol/ml), p = .002. Within the age-dependent serum concentration of pentosidine was higher (2148.5 ± 209.8) p = 0.988 in hypertension (˃ 70 years). A multiple linear stepwise regression analysis concludes that in patients with hypertension, serum pentosidine was significantly influenced with the age (standardized β = 0.440, 95%CI: 5.49–30.05, p = .006). The receiver operating characteristic curves for the presence of hypertension diagnosis had an area under the curve (AUC) of 0.675; (95% CI: 0.575–0.775, p = .003). The optimal cutoff value of pentosidine was 1120 pmol/ml with 97.4% sensitivity and 76.8% specificity. Serum pentosidine is significantly associated with hypertension in the study group also within their age group. It may be due to atherosclerosis and arterial stiffness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Miyazawa T, Nakagawa K, Shimasaki S, Nagai R. Lipid glycation and protein glycation in diabetes and atherosclerosis. Amino Acids. 2012;42:1163–70.

    Article  CAS  Google Scholar 

  2. Maillard L. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. CR Acad Sci Paris. 1912;154:66–8.

    CAS  Google Scholar 

  3. Semba Richard D, Nicklett EJ, Ferrucci L. Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol Ser A Biomed Sci Med Sci. 2010;65:963–75.

    Article  CAS  Google Scholar 

  4. Vlassara H, Palace MR. Diabetes and advanced glycation end products. J Intern Med. 2002;251:87–101.

    Article  CAS  Google Scholar 

  5. Koyama H, Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? Eur. J Clin Investig. 2010;40:623–35.

    Article  CAS  Google Scholar 

  6. Verzijl N, Bank RA, TeKoppele JM, DeGroot J. AGEing and osteoarthritis: a different perspective. Curr Opin Rheumatol. 2003;15:616–22.

    Article  Google Scholar 

  7. Koska J, Saremi A, Howell S, Bahn G, de Courten B, Ginsberg H, et al. Advanced Glycation end products, oxidation products, and incident cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2018;41:570–6.

    Article  CAS  Google Scholar 

  8. Erbersdobler Helmut F, Somoza V. Forty years of furosine–forty years of using Maillard reaction products as indicators of the nutritional quality of foods. Mol Nutr Food Res. 2007;51:423–30.

    Article  CAS  Google Scholar 

  9. Spagnoli LG, Mauriello A, Orlandi A, Sangiorgi G, Bonanno E. Age-related changes affecting atherosclerotic risk. Drugs Aging. 1998;4:275–98.

    Google Scholar 

  10. Reeg S, Grune T. Protein oxidation in aging: does it play a role in aging progression? Antioxid Redox Signal. 2015;23:239–55.

    Article  CAS  Google Scholar 

  11. Kerkeni M, Saïdi A, Bouzidi H, Yahya SB, Hammami M. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvasc Res. 2012;3:378–83.

    Article  Google Scholar 

  12. Haus JM, Carrithers JA, Trappe SW, Trappe TA. Collagen, cross-linking and advanced glycation end products in aging human skeletal muscle. J Appl Physiol. 2007;103:2068–76.

    Article  CAS  Google Scholar 

  13. Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res. 2013;3:239–45.

    Article  Google Scholar 

  14. Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism. 2005;54:345–50.

    Article  CAS  Google Scholar 

  15. Yamagishi S, et al. Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem. 1997;272:8723–30.

    Article  CAS  Google Scholar 

  16. Birlouez-Aragon I, Saavedra G, Tessier FJ, Galinier A, Ait-Ameur L, Lacoste F, et al. A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr. 2010;91:1220–6.

    Article  CAS  Google Scholar 

  17. Kerkeni M, Weiss IS, Jaisson S, Dandana A, Addad F, Gillery P, et al. Increased serum concentrations of pentosidine are related to presence and severity of coronary artery disease. Thromb Res. 2014;3:633–8.

    Article  Google Scholar 

  18. Nenna A, et al. Pharmacologic approaches against advanced glycation end products (AGEs) in diabetic cardiovascular disease. Res Cardiovasc Med. 2015;4:e26949.

    PubMed  PubMed Central  Google Scholar 

  19. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Götting C, et al. Benfotiamine prevents macro-and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. 2006;9:2064–71.

  20. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Cards investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;9435:685–96.

    Article  Google Scholar 

  21. Lonn E, Gerstein HC, Smieja M, Mann JF, Yusuf S. Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. Eur Heart J Suppl. 2003;5:A43–8.

    Article  CAS  Google Scholar 

  22. Byun K, Yoo YC, Son M, Lee J, Jeong GB, Park YM, et al. Advanced glycation end-products produced systemically and by macrophages: a common contributor to inflammation and degenerative diseases. Pharmacol Ther. 2017;177:44–55.

    Article  CAS  Google Scholar 

  23. Miyata T, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol. 1996;7:1198–206.

    CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by Department of Medicine, Institute of Medical Sciences, Banaras Hindu University India and the University Grant Commission Rajiv Gandhi National Fellowship (UGC-RGNF).

Author information

Authors and Affiliations

  1. Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India

    Neelam Tia, Chandra Shekhar Azad & Pritee Chaudhary

  2. Department of Biotechnology School of Engineering & Technology, ITM University, Gwalior, 474001, India

    Moti Lal

  3. Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India

    Manish Singh

  4. Department of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, 221005, India

    Indrajeet Singh Gambhir

Authors
  1. Neelam Tia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Moti Lal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chandra Shekhar Azad
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pritee Chaudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Manish Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Indrajeet Singh Gambhir
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: Dr. Indrajeet Singh Gambhir and Neelam Tia, Methodology: Neelam Tia, Chandra Shekhar Azad and Pritee Chaudhary, Formal analysis and investigation: Neelam Tia and Moti Lal, Writing: Neelam Tia, Writing - review and editing: Neelam Tia, Manish Singh, Funding acquisition: National Programme for Healthcare of the elderly (NPHCE) government of India and the University Grant Commission Rajiv Gandhi National Fellowship (UGC-RGNF). Supervision: Dr. Indrajeet Singh Gambhir

Corresponding author

Correspondence to Indrajeet Singh Gambhir.

Ethics declarations

Conflict of Interests

NT, ML, CSA, PC, MS and ISG have no conflict of interests that are directly relevant to the contents of this article.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tia, N., Lal, M., Azad, C.S. et al. Serum Pentosidine Level in Healthy Ageing and Its Association with Age-Related Disease. SN Compr. Clin. Med. 2, 2253–2259 (2020). https://doi.org/10.1007/s42399-020-00564-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s42399-020-00564-x

Keywords

Search

Navigation